TRPA1
Transient receptor potential cation channel subfamily A member 1
As of the edition of 20 October 2026, TRPA1 (transient receptor potential cation channel subfamily A member 1, UniProt O75762) has 5 drugs tested at it and 6 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O75762
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 18
- Disease areas
- Nervous system; Lungs and airways; Digestive system; Ear, nose and throat; Bones, joints and muscles; Cancer; Infections; Mouth and teeth
- Registered trials of its drugs
- 44
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Menthol | Marketed | Phase 4 | none listed |
| LY3526318 | Stopped | Phase 2 | none listed |
| GRC 17356 | Went quiet | Phase 2 | none listed |
| Propyphenazone | Marketed | Phase 3 | none listed |
| Butamben | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Undetermined | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Eli Lilly | Route A |
| Sanofi | Route B |
| Glenmark Pharmaceuticals | Route A |
The other 3 companies at TRPA1
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at TRPA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.